Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amoxicillin + minocycline is a combination of two antibiotics, amoxicillin and minocycline. Amoxicillin is a beta-lactam antibiotic in the penicillin class that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death. Minocycline is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to growing peptide chains. Both drugs are used individually for a wide range of bacterial infections; however, their combined use is not standard due to potential antagonistic interactions—minocycline may reduce the effectiveness of amoxicillin when used together[1][6]. This combination has been explored in some research settings (e.g., Helicobacter pylori eradication), but it is not an established or approved fixed-dose product[8]. Each drug retains its own spectrum and mechanism when co-administered.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + minocycline.